UK markets closed

Lonza Group Ltd (LZAGF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
803.45-38.55 (-4.58%)
At close: 3:25PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close842.00
Bid0.00 x 0
Ask0.00 x 0
Day's range803.45 - 826.71
52-week range558.29 - 852.25
Avg. volume164
Market cap59.772B
Beta (5Y monthly)0.38
PE ratio (TTM)77.60
EPS (TTM)10.35
Earnings dateN/A
Forward dividend & yield3.32 (0.40%)
Ex-dividend date10 May 2021
1y target estN/A
  • Reuters

    Vaccine business helps Lonza lift 2021 sales outlook

    ZURICH (Reuters) -Swiss contract drugmaker Lonza raised its 2021 outlook on Friday after booming business making ingredients for COVID-19 vaccines and strong growth elsewhere helped it beat analysts' expectations during the first half of the year. "In the prior year we provided an estimate for how much we expected from Moderna sales for 2021...the number is much higher given our ability to increase output at our existing facilities," Chief Financial Officer Rodolfo Savitzky told reporters. Its previous guidance had been for sales growth in the low double-digit range.

  • EQS Group

    Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin

    Lonza Group AG / Key word(s): Half Year Results23-Jul-2021 / 07:01 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad Hoc Release Pursuant to Art. 53 Listing Rules In H1 2021, Lonza continued its strong performance with 14.7%1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19 Continued focus on growth CAPEX investments, supported by strong business pipeline Expanded collaboratio